Project description:Candida auris clade III isolate B12039 was spread on YPD plate supplemented with 64 µg/ml fluconazole. Randomly 45 adaptors were chosen for further analysis. We did sequencing of them as as well as the parent.
Project description:Candida auris clade III isolate B12039 was spread on YPD plate supplemented with 128 µg/ml fluconazole. Randomly 39 adaptors were chosen for further analysis. We did sequencing of them as as well as the parent.
Project description:Candida auris clade III isolate B12039 was spread on YPD plate supplemented with 8 µg/ml tunicamycin. Randomly 27 adaptors were chosen for further analysis. We did sequencing of these 27 adaptors as well as the parent.
Project description:Candida auris clade III isolate B12039 was spread on YPD plate supplemented with 4 µg/ml tunicamycin. Randomly 27 adaptors were chosen for further analysis. We did sequencing of these 27 adaptors as well as the parent.
Project description:Candida auris clade III isolate B11221 was spread on YPD plate supplemented with 8 µg/ml tunicamycin. Randomly 18 adaptors were chosen for further analysis. We did sequencing of these 18 adaptors as well as the parent.
Project description:Candida auris wild type strain FY279 was used to tebuconazole adaptors. Transcriptomes of two adaptors, TJ42 and TJ44, were compared to wild type.
Project description:Candida auris clinical isolate FY279 was exposed to tebuconazole (32μg/ml). Randomly14 adaptors were chosen. 10 adaptors obtained resistance to tebuconazole. These resistant adaptors were sequenced.